NASDAQ: ALPN - Alpine Immune Sciences, Inc.

六个月盈利: -88.05%
部门: Healthcare

促销时间表 Alpine Immune Sciences, Inc.

先进的时间表 简单图表
Financial Markets by TradingView

关于公司

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.

更多详情
Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
添加到比较列表
添加到观察列表
添加到投资组合
添加价格通知

Выручка 0.0017
EBITDA -0.0415
Число акций ао 0.05 млрд
P/S 41.04
P/BV 2.42
EV/EBITDA -1.73
Цена ао 64.4
ISIN US02083G1004
Сайт https://www.alpineimmunesciences.com
Валюта usd
IPO date 2015-06-17
Sector Health Care
Industry Biotechnology
Валюта отчета usd
每日价格变化: 0% (7.7)
每周价格变化: 0% (7.7)
每月价格变化: -88.15% (64.97)
3个月内价格变化: -1.28% (7.8)
六个月内的价格变化: -88.05% (64.43)
每年价格变化: -24.51% (10.2)
3年内价格变化: -36.52% (12.13)
5年内价格变化: +58.11% (4.87)
年初以来价格变化: -42.45% (13.38)
所有参数

低估

姓名 意义 年级
P/S 16.49 1
P/BV 2.96 6
P/E 0 0
EV/EBITDA -21.45 0
全部的: 3.75

效率

姓名 意义 年级
ROA, % -8.43 0
ROE, % -9.81 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.227 10
全部的: 7.8

成长冲动

姓名 意义 年级
盈利能力 Revenue, % 3363.29 10
盈利能力 Ebitda, % 5.24 1
盈利能力 EPS, % -72.26 0
全部的: 4.2
更多详情

机构 体积 分享, %
Decheng Capital LLC 7083288 10.81
Decheng Capital Management III (Cayman), LLC 6708288 10.23
RA Capital Management, L.P. 4909763 7.49
Lynx1 Capital Management Lp 3813926 5.82
Great Point Partners LLC 3703433 5.65
Paradigm Biocapital Advisors LP 3176743 4.85
Frazier Life Sciences Management, L.P. 3131008 4.78
Blackrock Inc. 3058498 4.67
Cormorant Asset Management, LP 2550000 3.89
Orbimed Advisors LLC. 2535245 3.87



导师 职称 支付 出生年份
Dr. Mitchell H. Gold M.D. Executive Chairman & CEO 1.02M 1968 (56 年)
Dr. Stanford Peng M.D., Ph.D. President and Head of Research & Development 940.1k 1971 (53 年)
Mr. Paul Rickey Senior VP, CFO, Treasurer & Secretary 691.1k 1979 (45 年)
Dr. Remy Durand Ph.D. Chief Business Officer N/A 1985 (39 年)
Ms. M. Christina Yi Chief Technology Officer N/A 1977 (47 年)
Temre Johnson Head of IR & Corporate Communications
Dr. Wolfgang Dummer M.D., Ph.D. Chief Medical Officer 1966 (58 年)

地址: United States, Seattle. WA, 188 East Blaine Street - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.alpineimmunesciences.com